Advertisement

Antimicrobial Resistance Among Streptococcus pneumoniae

  • Catia Cillóniz
  • Carolina Garcia-Vidal
  • Adrian Ceccato
  • Antoni Torres
Chapter
Part of the Emerging Infectious Diseases of the 21st Century book series (EIDC)

Abstract

Antibiotic resistance in Streptococcus pneumoniae (pneumococcus), the main pathogen responsible for community-acquired pneumonia (CAP), meningitis, bacteremia, and otitis media, is a major concern for clinicians. This pathogen is associated with high rates of morbidity and mortality, especially among children under 2 years old, immunocompromised persons, and the elderly population. The major anti-pneumococcus agents are β-lactams and macrolides, with fluoroquinolones ranking third. The emergence of antibiotic-resistant pneumococcus due to overuse of antibiotics is a global concern. While the discovery of novel classes of antibiotics for the pneumococcus is at a standstill, significant progress in reducing the problem of resistance is associated with antibacterial vaccines. Nevertheless, the World Health Organization recently considered drug-resistant S. pneumoniae as ranking among the 12 bacteria, for which there is an urgent need for new treatments. A challenge is to slow the evolution of new strains that are resistant to the vaccines.

References

  1. 1.
    Goossens H. Antibiotic consumption and link to resistance. Clin Microbiol Infect. 2009;15(Suppl 3):12–5.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis. 2014;14:13.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Frieden T, Center for Disease Control. Antibiotic Resistance Threats in the United States 2013. US: U.S. Department of Health and Human Service, Center for Disease Control and Prevention; 2013.Google Scholar
  4. 4.
    Solomon SL, Oliver KB. Antibiotic resistance threats in the United States: stepping back from the brink. Am Fam Physician. 2014;89(12):938–41.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Anon. The bacterial challenge: time to react. EMEA-ECDC Technical Report 2009. 2009.Google Scholar
  6. 6.
    Adriaenssens N, Coenen S, Versporten A, Muller A, Vankerckhoven V, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): quality appraisal of antibiotic use in Europe. J Antimicrob Chemother. 2011;66(Suppl 6):vi71–7.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    World Health Organization (WHO). Antimicrobial resistance: global report on surveillance 2014, Antimicrobial resistance global surveillance report. Geneva: World Health Organization; 2014.Google Scholar
  8. 8.
    Weisfelt M, van de Beek D, Spanjaard L, Reitsma JB, de Gans J. Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. Lancet Neurol. 2006;5(2):123–9.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. N Engl J Med. 2006;354(1):44–53.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14(8):742–50.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Linares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect. 2010;16(5):402–10.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Lynch JP III, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med. 2009;30(2):210–38.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Choi SH, Kim EY, Kim YJ. Systemic use of fluoroquinolone in children. Korean J Pediatr. 2013;56(5):196–201.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Bradley JS, Jackson MA. The use of systemic and topical fluoroquinolones, e1034. Pediatrics. 2011;128(4):–e1045.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Arason VA, Kristinsson KG, Sigurdsson JA, Stefansdottir G, Molstad S, Gudmundsson S. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. BMJ. 1996;313(7054):387–91.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect. 2009;15(Suppl 3):16–20.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Hogberg L, Geli P, Ringberg H, Melander E, Lipsitch M, Ekdahl K. Age- and serogroup-related differences in observed durations of nasopharyngeal carriage of penicillin-resistant pneumococci. J Clin Microbiol. 2007;45(3):948–52.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Fenoll A, Granizo JJ, Aguilar L, et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol. 2009;47(4):1012–20.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Owens RC Jr, Shorr AF. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharm. 2009;66(12 Suppl 4):S23–30.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Jensen A, Valdorsson O, Frimodt-Moller N, Hollingshead S, Kilian M. Commensal streptococci serve as a reservoir for beta-lactam resistance genes in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2015;59(6):3529–40.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Cilloniz C, Ardanuy C, Vila J, Torres A. What is the clinical relevance of drug-resistant pneumococcus? Curr Opin Pulm Med. 2016;22(3):227–34.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Shortridge VD, Doern GV, Brueggemann AB, Beyer JM, Flamm RK. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994–1995. Clin Infect Dis. 1999;29(5):1186–8.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Sirekbasan L, Gonullu N, Sirekbasan S, Kuskucu M, Midilli K. Phenotypes and genotypes of macrolide-resistant streptococcus pneumoniae. Balkan Med J. 2015;32(1):84–8.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Calatayud L, Ardanuy C, Tubau F, et al. Serotype and genotype replacement among macrolide-resistant invasive Pneumococci in adults: mechanisms of resistance and association with different transposons. J Clin Microbiol. 2010;48(4):1310–6.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Grivea IN, Sourla A, Ntokou E, Chryssanthopoulou DC, Tsantouli AG, Syrogiannopoulos GA. Macrolide resistance determinants among Streptococcus pneumoniae isolates from carriers in Central Greece. BMC Infect Dis. 2012;12:255.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Lismond A, Carbonnelle S, Verhaegen J, et al. Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium. Int J Antimicrob Agents. 2012;39(3):208–16.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Wierzbowski AK, Nichol K, Laing N, et al. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004). J Antimicrob Chemother. 2007;60(4):733–40.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Hawkins PA, Chochua S, Jackson D, Beall B, McGee L. Mobile elements and chromosomal changes associated with MLS resistance phenotypes of invasive pneumococci recovered in the United States. Microb Drug Resist. 2015;21(2):121–9.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    El Ashkar S, Osman M, Rafei R, et al. Molecular detection of genes responsible for macrolide resistance among Streptococcus pneumoniae isolated in North Lebanon. J Infect Public Health. 2017;10(6):745–8.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Kawaguchiya M, Urushibara N, Aung MS, et al. Emerging non-PCV13 serotypes of noninvasive Streptococcus pneumoniae with macrolide resistance genes in northern Japan. New Microbes New Infect. 2016;9:66–72.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Azadegan A, Ahmadi A, Lari AR, Talebi M. Detection of the efflux-mediated erythromycin resistance transposon in Streptococcus pneumoniae. Ann Lab Med. 2015;35(1):57–61.PubMedCrossRefGoogle Scholar
  32. 32.
    Kim SH, Song JH, Chung DR, et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob Agents Chemother. 2012;56(3):1418–26.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Ramos V, Duarte C, Diaz A, Moreno J. Mobile genetic elements associated with erythromycin-resistant isolates of Streptococcus pneumoniae in Colombia. Biomedica. 2014;34(Suppl 1):209–16.PubMedGoogle Scholar
  34. 34.
    Reijtman V, Gagetti P, Faccone D, et al. Macrolide resistance in Streptococcus pneumoniae isolated from Argentinian pediatric patients suffering from acute otitis media. Rev Argent Microbiol. 2013;45(4):262–6.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Diawara I, Zerouali K, Katfy K, et al. Phenotypic and genotypic characterization of Streptococcus pneumoniae resistant to macrolide in Casablanca, Morocco. Infect Genet Evol. 2016;40:200–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Rachdi M, Boutiba-Ben Boubaker I, Moalla S, et al. Phenotypic and genotypic characterization of macrolide resistant Streptococcus pneumoniae in Tunisia. Pathol Biol (Paris). 2008;56(3):125–9.CrossRefGoogle Scholar
  37. 37.
    Reinert RR, Filimonova OY, Al-Lahham A, et al. Mechanisms of macrolide resistance among Streptococcus pneumoniae isolates from Russia. Antimicrob Agents Chemother. 2008;52(6):2260–2.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Ma X, Yao KH, Xie GL, et al. Characterization of erythromycin-resistant Streptococcus pneumoniae isolates causing invasive diseases in Chinese children. Chin Med J (Engl). 2013;126(8):1522–7.Google Scholar
  39. 39.
    Zhou L, Yu SJ, Gao W, Yao KH, Shen AD, Yang YH. Serotype distribution and antibiotic resistance of 140 pneumococcal isolates from pediatric patients with upper respiratory infections in Beijing, 2010. Vaccine. 2011;29(44):7704–10.PubMedCrossRefGoogle Scholar
  40. 40.
    Geng Q, Zhang T, Ding Y, et al. Molecular characterization and antimicrobial susceptibility of Streptococcus pneumoniae isolated from children hospitalized with respiratory infections in Suzhou, China. PLoS One. 2014;9(4):e93752.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Caierao J, Hawkins P, Sant’anna FH, et al. Serotypes and genotypes of invasive Streptococcus pneumoniae before and after PCV10 implementation in southern Brazil. PLoS One. 2014;9(10):e111129.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Fuller JD, McGeer A, Low DE. Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management. Eur J Clin Microbiol Infect Dis. 2005;24(12):780–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis. 2005;41(1):118–21.PubMedCrossRefGoogle Scholar
  44. 44.
    Urban C, Rahman N, Zhao X, et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis. 2001;184(6):794–8.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect. 2011;17(Suppl 6):E1–59.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Donhofer A, Franckenberg S, Wickles S, Berninghausen O, Beckmann R, Wilson DN. Structural basis for TetM-mediated tetracycline resistance. Proc Natl Acad Sci U S A. 2012;109(42):16900–5.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Moscoso M, Domenech M, Garcia E. Vancomycin tolerance in Gram-positive cocci. Environ Microbiol Rep. 2011;3(6):640–50.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Van BF, Reinert RR, Appelbaum PC, Tulkens PM, Peetermans WE. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs. 2007;67(16):2355–82.CrossRefGoogle Scholar
  50. 50.
    Sheppard C, Fry NK, Mushtaq S, et al. Rise of multidrug-resistant non-vaccine serotype 15A Streptococcus pneumoniae in the United Kingdom, 2001 to 2014. Euro Surveill. 2016;21(50):3042.Google Scholar
  51. 51.
    Richter SS, Diekema DJ, Heilmann KP, Dohrn CL, Riahi F, Doern GV. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother. 2014;58(11):6484–9.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Golden AR, Rosenthal M, Fultz B, et al. Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007–13. J Antimicrob Chemother. 2015;70(8):2199–202.PubMedCrossRefGoogle Scholar
  53. 53.
    Golden AR, Adam HJ, Zhanel GG. Invasive Streptococcus pneumoniae in Canada, 2011–2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F. Vaccine. 2016;34(23):2527–30.PubMedCrossRefGoogle Scholar
  54. 54.
    Olarte L, Kaplan SL, Barson WJ, et al. Emergence of Multidrug-resistant Pneumococcal Serotype 35B among U.S. Children. J Clin Microbiol. 2017;55(3):724–34.Google Scholar
  55. 55.
    Nakano S, Fujisawa T, Ito Y, et al. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012–2014. Vaccine. 2016;34(1):67–76.PubMedCrossRefGoogle Scholar
  56. 56.
    Elshafie S, Taj-Aldeen SJ. Emerging resistant serotypes of invasive Streptococcus pneumoniae. Infect Drug Resist. 2016;9:153–60.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Bahy RH, Hamouda HM, Shahat AS, Yassin AS, Amin MA. Emergence of neoteric serotypes among multidrug resistant strains of Streptococcus pneumoniae prevalent in Egypt. Jundishapur J Microbiol. 2016;9(4):e30708.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Aspa J, Rajas O, Rodríguez de Castro F, et al. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis. 2004;38(6):787–98.PubMedCrossRefGoogle Scholar
  59. 59.
    Pallares R, Gudiol F, Linares J, et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med. 1987;317:18–22.PubMedCrossRefGoogle Scholar
  60. 60.
    Tsai HY, Lauderdale TL, Wang JT, et al. Updated antibiotic resistance and clinical spectrum of infections caused by Streptococcus pneumoniae in Taiwan: emphasis on risk factors for penicillin nonsusceptibilities. J Microbiol Immunol Infect. 2013;46(5):345–51.PubMedCrossRefGoogle Scholar
  61. 61.
    Ruhe JJ, Hasbun R. Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clin Infect Dis. 2003;36(9):1132–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Ruhe JJ, Myers L, Mushatt D, Hasbun R. High-level penicillin-nonsusceptible Streptococcus pneumoniae bacteremia: identification of a low-risk subgroup. Clin Infect Dis. 2004;38(4):508–14.PubMedCrossRefGoogle Scholar
  63. 63.
    Mollendorf CV, Cohen C, De Gouveia L, et al. Factors associated with ceftriaxone nonsusceptibility of Streptococcus pneumoniae: analysis of South African national surveillance data, 2003 to 2010. Antimicrob Agents Chemother. 2014;58(6):3293–305.CrossRefGoogle Scholar
  64. 64.
    Bogaert D, de Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4(3):144–54.CrossRefPubMedGoogle Scholar
  65. 65.
    Gritzfeld JF, Wright AD, Collins AM, et al. Experimental human pneumococcal carriage. J Vis Exp. 2013;(72):50115.Google Scholar
  66. 66.
    Vasoo S, Singh K, Hsu LY, et al. Increasing antibiotic resistance in Streptococcus pneumoniae colonizing children attending day-care centres in Singapore. Respirology. 2011;16(8):1241–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Jain A, Kumar P, Awasthi S. High nasopharyngeal carriage of drug resistant Streptococcus pneumoniae and Haemophilus influenzae in North Indian schoolchildren. Trop Med Int Heal. 2015;10:234–9.CrossRefGoogle Scholar
  68. 68.
    Dunais B, Bruno-Bazureault P, Carsenti-Dellamonica H, Touboul P, Pradier C. A decade-long surveillance of nasopharyngeal colonisation with Streptococcus pneumoniae among children attending day-care centres in south-eastern France: 1999–2008. Eur J Clin Microbiol Infect Dis. 2011;30(7):837–43.PubMedCrossRefGoogle Scholar
  69. 69.
    Nuorti JP, Butler JC, Crutcher JM, et al. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med. 1998;338:1861–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Van Eldere J, Mera RM, Miller LA, Poupard JA, Amrine-Madsen H. Risk factors for development of multiple-class resistance to Streptococcus pneumoniae Strains in Belgium over a 10-year period: antimicrobial consumption, population density, and geographic location. Antimicrob Agents Chemother. 2007;51(10):3491–7.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    van de Sande-Bruinsma N, Grundmann H, Verloo D, et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis. 2008;14(11):1722–30.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Farshad AA, Enferadi M, Bakand S, Jamshidi OR, Mirkazemi R. Penicillin dust exposure and penicillin resistance among pharmaceutical workers in Tehran, Iran. Int J Occup Environ Health. 2016:22(3): 218–23.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Hare KM, Leach AJ, Morris PS, et al. Impact of recent antibiotics on nasopharyngeal carriage and lower airway infection in Indigenous Australian children with non-cystic fibrosis bronchiectasis. Int J Antimicrob Agents. 2012;40(4):365–9.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Metlay JP, Fishman NO, Joffe MM, Kallan MJ, Chittams JL, Edelstein PH. Macrolide resistance in adults with bacteremic pneumococcal pneumonia. Emerg Infect Dis. 2006;12(8):1223–30.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Dias R, Canica M. Trends in resistance to penicillin and erythromycin of invasive pneumococci in Portugal. Epidemiol Infect. 2008;136(7):928–39.PubMedCrossRefGoogle Scholar
  76. 76.
    Baek JY, Kim SH, Kang CI, et al. Prevalence of antimicrobial resistant Streptococcus pneumoniae serotype 11A isolates in Korea, during 2004–2013, due to the increase of multidrug-resistant clone, CC166. Infect Genet Evol. 2016;38:122–5.PubMedCrossRefGoogle Scholar
  77. 77.
    Zhou L, Ma X, Gao W, et al. Molecular characteristics of erythromycin-resistant Streptococcus pneumoniae from pediatric patients younger than five years in Beijing, 2010. BMC Microbiol. 2012;12:228.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Pan F, Han L, Huang W, et al. Serotype distribution, antimicrobial susceptibility, and molecular epidemiology of Streptococcus pneumoniae Isolated from children in Shanghai, China. PLoS One. 2015;10(11):e0142892.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Hadjipanayis A, Efstathiou E, Alexandrou M, et al. Nasopharyngeal Pneumococcal Carriage among Healthy Children in Cyprus Post Widespread Simultaneous Implementation of PCV10 and PCV13 Vaccines. PLoS One. 2016;11(10):e0163269.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Vanderkooi OG, McConnell A, Church DL, Kellner JD. Antimicrobial susceptibility of invasive and lower respiratory tract isolates of Streptococcus pneumoniae, 1998 to 2007. Can J Infect Dis Med Microbiol. 2009;20(4):e139–44.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Matsumoto A, Hosoya M, Kawasaki Y, Katayose M, Kato K, Suzuki H. The emergence of drug-resistant Streptococcus pneumoniae and host risk factors for carriage of drug-resistant genes in northeastern Japan. Jpn J Infect Dis. 2007;60(1):10–3.PubMedPubMedCentralGoogle Scholar
  82. 82.
    Grivea IN, Priftis KN, Giotas A, et al. Dynamics of pneumococcal carriage among day-care center attendees during the transition from the 7-valent to the higher-valent pneumococcal conjugate vaccines in Greece. Vaccine. 2014;32(48):6513–20.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Zuccotti G, Mameli C, Daprai L, et al. Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era. Vaccine. 2014;32(5):527–34.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Korona-Glowniak I, Siwiec R, Malm A. Resistance determinants and their association with different transposons in the antibiotic-resistant Streptococcus pneumoniae. Biomed Res Int. 2015;2015:836496.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Ding Y, Geng Q, Tao Y, et al. Etiology and epidemiology of children with acute otitis media and spontaneous otorrhea in Suzhou, China. Pediatr Infect Dis J. 2015;34(5):e102–6.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Abdelnour A, Arguedas A, Dagan R, et al. Etiology and antimicrobial susceptibility of middle ear fluid pathogens in Costa Rican children with otitis media before and after the introduction of the 7-valent pneumococcal conjugate vaccine in the National Immunization Program: acute otitis media microbiology in Costa Rican children. Medicine (Baltimore). 2015;94(2):e320.CrossRefGoogle Scholar
  87. 87.
    Pumarola F, Mares J, Losada I, et al. Microbiology of bacteria causing recurrent acute otitis media (AOM) and AOM treatment failure in young children in Spain: shifting pathogens in the post-pneumococcal conjugate vaccination era. Int J Pediatr Otorhinolaryngol. 2013;77(8):1231–6.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Arason VA, Sigurdsson JA, Erlendsdottir H, Gudmundsson S, Kristinsson KG. The role of antimicrobial use in the epidemiology of resistant pneumococci: a 10-year follow up. Microb Drug Resist. 2006;12(3):169–76.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis. 2001;32(5):701–7.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Kang CI, Song JH, Kim SH, et al. Risk factors for levofloxacin-nonsusceptible Streptococcus pneumoniae in community-acquired pneumococcal pneumonia: a nested case-control study. Eur J Clin Microbiol Infect Dis. 2014;33(1):55–9.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Kim ES, Hooper DC. Clinical importance and epidemiology of quinolone resistance. Infect Chemother. 2014;46(4):226–38.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Kuster SP, Rudnick W, Shigayeva A, et al. Previous antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: results from prospective surveillance. Clin Infect Dis. 2014;59(7):944–52.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Wolter N, Du Plessis M, Von Gottberg A, De Gouveia L, Klugman KP. Molecular characterization of emerging non-levofloxacin-susceptible pneumococci isolated from children in South Africa. J Clin Microbiol. 2009;47(5):1319–24.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Ben-David D, Schwaber MJ, Adler A, et al. Persistence and complex evolution of fluoroquinolone-resistant Streptococcus pneumoniae clone. Emerg Infect Dis. 2014;20(5):799–805.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Isea-Pena MC, Sanz-Moreno JC, Esteban J, Fernandez-Roblas R, Fernandez-Guerrero ML. Risk factors and clinical significance of invasive infections caused by levofloxacin-resistant Streptococcus pneumoniae. Infection. 2013;41(5):935–9.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Kupronis BA, Richards CL, Whitney CG. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community. J Am Geriatr Soc. 2003;51(11):1520–5.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis. 2005;40(9):1288–97.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Thabit AK, Crandon JL, Nicolau DP. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opin Pharmacother. 2015;16(2):159–77.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Song JH, Dagan R, Klugman KP, Fritzell B. The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine. 2012;30(17):2728–37.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Thummeepak R, Leerach N, Kunthalert D, Tangchaisuriya U, Thanwisai A, Sitthisak S. High prevalence of multi-drug resistant Streptococcus pneumoniae among healthy children in Thailand. J Infect Public Health. 2015;8(3):274–81.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Jin P, Kong F, Xiao M, et al. First report of putative Streptococcus pneumoniae serotype 6D among nasopharyngeal isolates from Fijian children. J Infect Dis. 2009;200(9):1375–80.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Oliver MB, van der Linden MP, Kuntzel SA, Saad JS, Nahm MH. Discovery of Streptococcus pneumoniae serotype 6 variants with glycosyltransferases synthesizing two differing repeating units. J Biol Chem. 2015;290(44):26474–5.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Calix JJ, Porambo RJ, Brady AM, et al. Biochemical, genetic, and serological characterization of two capsule subtypes among Streptococcus pneumoniae Serotype 20 strains: discovery of a new pneumococcal serotype. J Biol Chem. 2012;287(33):27885–94.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Jauneikaite E, Tocheva AS, Jefferies JM, et al. Current methods for capsular typing of Streptococcus pneumoniae. J Microbiol Methods. 2015;113:41–9.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson KG, Spratt BG. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis. 2004;190(7):1203–11.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Browall S, Backhaus E, Naucler P, et al. Clinical manifestations of invasive pneumococcal disease by vaccine and non-vaccine types. Eur Respir J. 2014;44(6):1646–57.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Sjostrom K, Spindler C, Ortqvist A, et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis. 2006;42(4):451–9.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Henriques-Normark B, Blomberg C, Dagerhamn J, Battig P, Normark S. The rise and fall of bacterial clones: Streptococcus pneumoniae. Nat Rev Microbiol. 2008;6(11):827–37.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Meropol SB, Stange KC, Jacobs MR, Weiss JK, Bajaksouzian S, Bonomo RA. Bacterial colonization and antibiotic resistance in a prospective cohort of newborn infants during the first year of life. Open Forum Infect Dis. 2016;3(4):ofw221.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Boken DJ, Chartrand SA, Goering RV, Kruger R, Harrison CJ. Colonization with penicillin-resistant Streptococcus pneumoniae in a child-care center. Pediatr Infect Dis J. 1995;14(10):879–84.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States. 2013.Google Scholar
  112. 112.
    Navarro TA, Dias JG, Quinten C, et al. European enhanced surveillance of invasive pneumococcal disease in 2010: data from 26 European countries in the post-heptavalent conjugate vaccine era. Vaccine. 2014;32(29):3644–50.CrossRefGoogle Scholar
  113. 113.
    European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2012. 2012.Google Scholar
  114. 114.
    Jones RN, Sader HS, Mendes RE, Flamm RK. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998–2011). Diagn Microbiol Infect Dis. 2013;75(1):107–9.PubMedCrossRefGoogle Scholar
  115. 115.
    Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis. 2009;15(8):1260–4.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Xiao Y, Wei Z, Shen P, et al. Bacterial-resistance among outpatients of county hospitals in China: significant geographic distinctions and minor differences between central cities. Microbes Infect. 2015;17(6):417–25.PubMedCrossRefGoogle Scholar
  117. 117.
    Cilloniz C, Albert RK, Liapikou A, et al. The effect of macrolide-resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia. Am J Respir Crit Care Med. 2015;191(11):1265–72.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Pletz MW, van der Linden M, von Baum H, Duesberg CB, Klugman KP, Welte T. Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage. Int J Med Microbiol. 2011;301(1):53–7.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Jacobs E, Dalhoff A, Korfmann G. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study). Int J Antimicrob Agents. 2009;33(1):52–7.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Ho PL, Cheng VC, Chow KH. Decreasing prevalence of levofloxacin-resistant Streptococcus pneumoniae in Hong Kong, 2001 to 2007. J Antimicrob Chemother. 2009;63(4):836–8.PubMedCrossRefPubMedCentralGoogle Scholar
  121. 121.
    Vila-Corcoles A, Ochoa-Gondar O. Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice. Drugs Aging. 2013;30(5):263–76.PubMedCrossRefPubMedCentralGoogle Scholar
  122. 122.
    Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354(14):1455–63.PubMedCrossRefPubMedCentralGoogle Scholar
  123. 123.
    Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368(9546):1495–502.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Gertz RE Jr, Li Z, Pimenta FC, et al. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis. 2010;201(5):770–5.PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine. 2010;28(26):4249–59.PubMedCrossRefPubMedCentralGoogle Scholar
  126. 126.
    Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–9.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    van der Linden M, Perniciaro S, Imohl M. Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis. 2015;15:207.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Garcia-Vidal C, Ardanuy C, Tubau F, et al. Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax. 2010;65(1):77–81.PubMedCrossRefPubMedCentralGoogle Scholar
  129. 129.
    Mongardon N, Max A, Bougle A, et al. Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study. Crit Care. 2012;16(4):R155.PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    Kaplan SL, Mason EO Jr. Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Rev. 1998;11(4):628–44.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Schroeder MR, Stephens DS. Macrolide resistance in Streptococcus pneumoniae. Front Cell Infect Microbiol. 2016;6:98.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Endimiani A, Brigante G, Bettaccini AA, Luzzaro F, Grossi P, Toniolo AQ. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia. BMC Infect Dis. 2005;5:106.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Kim L, McGee L, Tomczyk S, Beall B. Biological and epidemiological features of antibiotic-resistant Streptococcus pneumoniae in pre- and post-conjugate vaccine eras: a United States perspective. Clin Microbiol Rev. 2016;29(3):525–52.PubMedPubMedCentralCrossRefGoogle Scholar
  134. 134.
    Kang CI, Song JH, Kim SH, et al. Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases: a post hoc analysis of a prospective cohort. Infection. 2013;41(1):151–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Catia Cillóniz
    • 1
  • Carolina Garcia-Vidal
    • 2
  • Adrian Ceccato
    • 3
  • Antoni Torres
    • 1
  1. 1.Department of PneumologyInstitut Clinic del Tórax, Hospital Clinic of Barcelona – Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB) – SGR 911 – Ciber de Enfermedades Respiratorias (Ciberes)BarcelonaSpain
  2. 2.Infectious Disease DepartmentHospital Clinic of BarcelonaBarcelonaSpain
  3. 3.Department of PneumologyHospital Nacional Alejandro PosadasPalomarArgentina

Personalised recommendations